MA54087A - Sels cristallins d'un inhibiteur de la kallicréine plasmatique - Google Patents
Sels cristallins d'un inhibiteur de la kallicréine plasmatiqueInfo
- Publication number
- MA54087A MA54087A MA054087A MA54087A MA54087A MA 54087 A MA54087 A MA 54087A MA 054087 A MA054087 A MA 054087A MA 54087 A MA54087 A MA 54087A MA 54087 A MA54087 A MA 54087A
- Authority
- MA
- Morocco
- Prior art keywords
- kallicrein
- inhibitor
- plasma
- crystalline salts
- crystalline
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862754983P | 2018-11-02 | 2018-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54087A true MA54087A (fr) | 2022-02-09 |
Family
ID=70457981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA054087A MA54087A (fr) | 2018-11-02 | 2019-11-01 | Sels cristallins d'un inhibiteur de la kallicréine plasmatique |
Country Status (21)
Country | Link |
---|---|
US (4) | US10662160B1 (fr) |
EP (1) | EP3873463A4 (fr) |
JP (2) | JP2022505670A (fr) |
KR (1) | KR20210087037A (fr) |
CN (1) | CN112969458A (fr) |
AR (1) | AR116951A1 (fr) |
AU (1) | AU2019374115A1 (fr) |
BR (1) | BR112021008249A2 (fr) |
CA (1) | CA3117123A1 (fr) |
CL (1) | CL2021001094A1 (fr) |
CO (1) | CO2021007172A2 (fr) |
EA (1) | EA202191192A1 (fr) |
IL (1) | IL282454A (fr) |
MA (1) | MA54087A (fr) |
MX (1) | MX2021004917A (fr) |
PE (1) | PE20211280A1 (fr) |
PH (1) | PH12021550883A1 (fr) |
SG (1) | SG11202103804TA (fr) |
TW (1) | TW202031255A (fr) |
UY (1) | UY38438A (fr) |
WO (1) | WO2020092898A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016011468A (es) | 2014-03-07 | 2017-01-23 | Biocryst Pharm Inc | Inhibidores de calicreína plasmática humana. |
AR116951A1 (es) | 2018-11-02 | 2021-06-30 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
WO2021025969A1 (fr) * | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide de bérotralstat |
CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4559157A (en) * | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
MX2012013331A (es) | 2010-05-19 | 2013-02-01 | Sandoz Ag | Purificacion de posaconazol y de intermediarios de posaconazol. |
GB201212081D0 (en) * | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
MX2016011468A (es) * | 2014-03-07 | 2017-01-23 | Biocryst Pharm Inc | Inhibidores de calicreína plasmática humana. |
AR116951A1 (es) | 2018-11-02 | 2021-06-30 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
-
2019
- 2019-10-31 AR ARP190103187A patent/AR116951A1/es unknown
- 2019-10-31 UY UY0001038438A patent/UY38438A/es unknown
- 2019-11-01 CN CN201980072995.3A patent/CN112969458A/zh active Pending
- 2019-11-01 CA CA3117123A patent/CA3117123A1/fr active Pending
- 2019-11-01 BR BR112021008249-2A patent/BR112021008249A2/pt unknown
- 2019-11-01 JP JP2021522086A patent/JP2022505670A/ja active Pending
- 2019-11-01 WO PCT/US2019/059385 patent/WO2020092898A1/fr unknown
- 2019-11-01 SG SG11202103804TA patent/SG11202103804TA/en unknown
- 2019-11-01 US US16/671,649 patent/US10662160B1/en active Active
- 2019-11-01 MA MA054087A patent/MA54087A/fr unknown
- 2019-11-01 MX MX2021004917A patent/MX2021004917A/es unknown
- 2019-11-01 AU AU2019374115A patent/AU2019374115A1/en active Pending
- 2019-11-01 EP EP19877809.4A patent/EP3873463A4/fr active Pending
- 2019-11-01 EA EA202191192A patent/EA202191192A1/ru unknown
- 2019-11-01 PE PE2021000587A patent/PE20211280A1/es unknown
- 2019-11-01 TW TW108139655A patent/TW202031255A/zh unknown
- 2019-11-01 KR KR1020217013734A patent/KR20210087037A/ko active Search and Examination
-
2020
- 2020-02-06 US US16/784,016 patent/US11117867B2/en active Active
-
2021
- 2021-04-20 IL IL282454A patent/IL282454A/en unknown
- 2021-04-21 PH PH12021550883A patent/PH12021550883A1/en unknown
- 2021-04-27 CL CL2021001094A patent/CL2021001094A1/es unknown
- 2021-05-31 CO CONC2021/0007172A patent/CO2021007172A2/es unknown
- 2021-09-02 US US17/465,181 patent/US11618733B2/en active Active
-
2023
- 2023-03-10 US US18/120,073 patent/US20240109844A1/en active Pending
-
2024
- 2024-05-27 JP JP2024085295A patent/JP2024109860A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2021007172A2 (es) | 2021-06-10 |
CN112969458A (zh) | 2021-06-15 |
JP2024109860A (ja) | 2024-08-14 |
TW202031255A (zh) | 2020-09-01 |
US20240109844A1 (en) | 2024-04-04 |
PH12021550883A1 (en) | 2022-02-21 |
AR116951A1 (es) | 2021-06-30 |
EP3873463A1 (fr) | 2021-09-08 |
SG11202103804TA (en) | 2021-05-28 |
US20200140389A1 (en) | 2020-05-07 |
US11117867B2 (en) | 2021-09-14 |
PE20211280A1 (es) | 2021-07-19 |
JP2022505670A (ja) | 2022-01-14 |
US20200308118A1 (en) | 2020-10-01 |
KR20210087037A (ko) | 2021-07-09 |
UY38438A (es) | 2020-05-29 |
US11618733B2 (en) | 2023-04-04 |
EA202191192A1 (ru) | 2021-09-23 |
WO2020092898A1 (fr) | 2020-05-07 |
MX2021004917A (es) | 2021-06-18 |
EP3873463A4 (fr) | 2022-06-22 |
AU2019374115A1 (en) | 2021-06-03 |
IL282454A (en) | 2021-06-30 |
CL2021001094A1 (es) | 2021-10-15 |
US10662160B1 (en) | 2020-05-26 |
BR112021008249A2 (pt) | 2021-08-03 |
US20220204454A1 (en) | 2022-06-30 |
CA3117123A1 (fr) | 2020-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
MA54087A (fr) | Sels cristallins d'un inhibiteur de la kallicréine plasmatique | |
MA42606A (fr) | Sels d'un inhibiteur de lsd1 | |
MA50223A (fr) | Sels inhibiteurs de ferroportine | |
MA42780A (fr) | Sels d'un inhibiteur de la kinase pim | |
IL266548A (en) | Crystalline forms of magl inhibitor | |
MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
DK3999038T3 (da) | Orale formuleringer af en kardial sarcomer-inhibitor | |
MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
IL287668A (en) | Crystalline forms of btk inhibitor | |
IL289929A (en) | Crystal forms of cd73 inhibitor | |
DK3826982T3 (da) | Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer | |
MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
AR104935A1 (es) | Formas cristalinas de un inhibidor de histona deacetilasa | |
IL281168A (en) | Crystal forms of the quinazole compound and its hydrochloride salts | |
HUE065266T2 (hu) | Egy tienopirimidin új kristályos formái MCL-1 inhibitorként | |
SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
IL285427A (en) | Crystal forms of jak2 inhibitor | |
IL279953A (en) | Crystal forms of LTA4H inhibitor | |
SG11202107225SA (en) | Crystalline form of a cdk inhibitor | |
MA41599A (fr) | Formes cristallines d'un composé pyrrolopyridine | |
IL292847A (en) | Crystalline forms of magl inhibitor | |
DK3898638T3 (da) | Krystallinske former af en par4-hæmmer | |
IL292206A (en) | The salts of a compound and its crystalline forms | |
SG11202105355XA (en) | Crystalline salts of corydalmine |